Oct 26 (Reuters) – Castle Biosciences Inc: * NEW DATA AT AMERICAN COLLEGE OF GASTROENTEROLOGY ANNUAL MEETING SHOW TISSUECYPHER® PROVIDES ACTIONABLE RISK INSIGHTS THAT INFLUENCE CLINICAL MANAGEMENT AND PROMPT RISK-ALIGNED INTERVENTION IN BARRETT’S ESOPHAGUS * CASTLE BIOSCIENCES INC – TISSUECYPHER SHOWS 34% AND 62% FIVE-YEAR PROGRESSION RISK Source text: Further company coverage:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

The post BRIEF-Castle Biosciences Inc Says Tissuecypher® Provides Actionable Risk Insights That Influence Clinical Management And Prompt Risk-Aligned Intervention In Barrett’s Esophagus appeared first on The Sunday Guardian.

See Full Page